Peptide receptor radionuclide therapy, or PRRT, uses a molecule that binds to a tumor-associated receptor to carry a radioactive payload. Lutetium Lu 177 dotatate is FDA-approved for somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors. Its adult approval dates to 2018, and the indication was extended to patients aged 12 years and older in 2024. Treatment eligibility and planning require specialist assessment; the presence of a neuroendocrine tumor alone does not establish suitability. [1]

Randomized studies have strengthened the evidence base. NETTER-1 demonstrated improved progression-free survival with lutetium-177 dotatate plus octreotide compared with high-dose octreotide in patients with progressive, advanced midgut NETs. That study population matters when interpreting its findings: results from one primary site and clinical setting should not be presented as identical evidence for every neuroendocrine cancer. [2]

NETTER-2 subsequently studied first-line lutetium-177 dotatate plus octreotide in newly diagnosed, advanced, well-differentiated, somatostatin receptor–positive gastroenteropancreatic NETs with higher grade 2 or grade 3 disease. The trial reported a substantial progression-free survival improvement compared with high-dose octreotide. Its enrolled Ki-67 range was 10% to 55%; it was not a trial of all grades, all receptor profiles, or poorly differentiated neuroendocrine carcinoma. [3]

Progress also leaves difficult research questions. How should treatment be sequenced with other effective options? Which markers best predict lasting benefit or resistance? Can dosimetry help optimize treatment while protecting healthy organs? How should new radionuclides or combinations be evaluated?

These questions should be approached through studies that specify the population, comparator, outcomes, and safety monitoring. Longer time without progression is a meaningful endpoint, but it should not be described as proof of cure. PRRT also has risks, including bone marrow and kidney toxicity, which require appropriate assessment and follow-up. [4]

The institute’s prospective interest is in research that improves the precision, durability, and practical delivery of radionuclide treatment. Established therapy provides a foundation for the next question—and each new approach needs evidence of its own.